Prolidase-proline oxidase axis is engaged in apoptosis induction by birch buds flavonol santin in endometrial adenocarcinoma cell line DOI Creative Commons
Łukasz Szoka, Jolanta Nazaruk,

Joanna Giegiel

et al.

Frontiers in Molecular Biosciences, Journal Year: 2023, Volume and Issue: 10

Published: Sept. 6, 2023

Cancer of the corpus uteri and cervix uteri, collectively ranks second among new cancer cases in women after breast cancer. Therefore, investigation anticancer agents identifying molecular targets presents a challenge to improve effectiveness chemotherapy. In this study, antiproliferative activity flavonoids derived from buds silver birch downy was evaluated endometrial Ishikawa cells cervical HeLa cells. It found that flavanol santin reduced viability both cell lines better than other flavonoids, including apigenin luteolin. Moreover, slightly higher induced by chemotherapy drug, cisplatin. Santin promoted intrinsic extrinsic apoptosis pathways cells, but it had low toxicity normal fibroblasts. The mechanisms impairing included induction oxidative proline catabolism, however different ways used. increase oxidation due activation p53 leading oxidase upregulation. contrast, having basal level significantly treatment decreased its expression. Nevertheless, these since increased expression prolidase, an enzyme providing protein degradation. lines, associated with generation reactive oxygen species reduction viability. Our findings reveal involvement identify role prolidase oxidase-dependent apoptosis.

Language: Английский

2023 global inventory of commercial molecular tests for human papillomaviruses (HPV) DOI Creative Commons
Mario Poljak, Anja Oštrbenk Valenčak, Kate Cuschieri

et al.

Journal of Clinical Virology, Journal Year: 2024, Volume and Issue: 172, P. 105671 - 105671

Published: March 14, 2024

To suit the needs of human papillomaviruses (HPV) community comprehensively, a range commercial HPV tests with different performance characteristics are required. Four periodic inventories molecular present in global market were published previously 2010, 2012, 2015 and 2020. For fifth inventory, data retrieved from internal files detailed search using main bibliographic databases as well general internet without period or language restrictions was performed December 2023. At least 264 distinct (and 511 test variants) available globally A small 2020-2023 net increase total numbers observed, but strong introduction/withdrawal dynamic: 86 new 141 introduced 76 55 withdrawn last four years. Although quality improvement some recorded, half all still single peer-reviewed publication, 79 % evidence that demonstrate line requirements agreed community. Only relatively pool fulfill operational/performance required to meet cervical cancer screening challenge. clinical analytical many largely unknown, such used worldwide daily practice research, potentially deleterious consequences. Due this long-lasting unfavorable situation, significant scope for persists both manufacturers

Language: Английский

Citations

13
Advanced technologies towards improved HPV diagnostics DOI Creative Commons
Martin Bartošík, Ludmila Moráňová, Nasim Izadi

et al.

Journal of Medical Virology, Journal Year: 2024, Volume and Issue: 96(2)

Published: Jan. 31, 2024

Abstract Persistent infection with high‐risk types of human papillomaviruses (HPV) is a major cause cervical cancer, and an important factor in other malignancies, for example, head neck cancer. Despite recent progress screening vaccination, the incidence mortality are still relatively high, especially low‐income countries. The financial burden associated treatment could be decreased if simple, rapid, inexpensive technology HPV testing becomes available, targeting individuals further monitoring increased risk developing Commercial tests available market often expensive, time‐consuming, require sophisticated instrumentation, which limits their more widespread utilization. To address these challenges, novel technologies being implemented also diagnostics that include isothermal amplification techniques, lateral flow assays, CRISPR‐Cas‐based systems, as well microfluidics, paperfluidics lab‐on‐a‐chip devices, ideal point‐of‐care decentralized settings. In this review, we first evaluate current commercial tests, followed by description advanced technologies, explanation principles, critical evaluation strengths weaknesses, suggestions possible implementation into medical diagnostics.

Language: Английский

Citations

12
mRNA‐HPV vaccine encoding E6 and E7 improves therapeutic potential for HPV‐mediated cancers via subcutaneous immunization DOI
Seonghyun Lee, Hyunho Yoon,

Seol Hee Hong

et al.

Journal of Medical Virology, Journal Year: 2023, Volume and Issue: 95(12)

Published: Dec. 1, 2023

Abstract The E6 and E7 proteins of specific subtypes human papillomavirus (HPV), including HPV 16 18, are highly associated with cervical cancer as they modulate cell cycle regulation. aim this study was to investigate the potential antitumor effects a messenger RNA‐HPV therapeutic vaccine (mHTV) containing nononcogenic proteins. To achieve this, C57BL/6j mice were injected via both intramuscular subcutaneous routes, resulting evaluated. mHTV immunization markedly induced robust T cell‐mediated immune responses significantly suppressed tumor growth in orthotopic tumor‐implanted mouse model, significant infiltration cells into tissues. Tumor retransplantation at day 62 postprimary vaccination completely halted progression all mHTV‐treated mice. Furthermore, expansion reduced upon TC‐1 transplantation 160 days after last immunization. Immunization rhesus monkeys elicited promising responses. immunogenicity nonhuman primates provides strong evidence for clinical application against HPV‐related cancers humans. All data suggest that can be used prophylactic vaccine.

Language: Английский

Citations

13
HPV and Cervical Cancer—Biology, Prevention, and Treatment Updates DOI Creative Commons
Emilia Włoszek,

Katherine Krupa,

Eliza Skrok

et al.

Current Oncology, Journal Year: 2025, Volume and Issue: 32(3), P. 122 - 122

Published: Feb. 22, 2025

One of the most significant breakthroughs in cancer research has been identification persistent infection with certain human papillomaviruses (HPV) genotypes as cause cervical cancer. Since then, a range diagnostic and therapeutic methods developed based on this discovery. This article aims to describe latest updates biology, prevention, treatment HPV-related The current state knowledge regarding vaccinations, tests, therapies is presented. WHO guidelines vaccinations are presented, well announcements upcoming changes. final part summarizes promising new methods, perspectives findings self-administered use vaccines, circulating cell-free DNA diagnosis. Despite progress made recent years, strategy vaccination testing remains cornerstone fight against

Language: Английский

Citations

0
Enhancing Cervical Cancer Screening: New Diagnostic Methodologies, Triage, and Risk Stratification in Prevention and Treatment DOI Creative Commons
Nazira Kamzayeva, Gauri Bapayeva, Milan Terzić

et al.

Life, Journal Year: 2025, Volume and Issue: 15(3), P. 367 - 367

Published: Feb. 26, 2025

Human papillomavirus (HPV) is a well-established etiological factor in the development of precancerous cervical lesions and cancer. This narrative review synthesizes current evidence on global prevalence, genotype distribution, pathophysiological mechanisms HPV infection, emphasizing regional epidemiological variations that influence prevention treatment strategies. Particular attention given to high-risk genotypes, their role carcinogenesis, impact co-infections cervicovaginal microbiota infection persistence disease progression. Advances diagnostic methodologies, including E6/E7 oncoprotein detection, DNA methylation, microRNA-based assays, are examined context improving screening accuracy early detection. Furthermore, explores psychological implications diagnosis underscores importance integrating psychosocial support into clinical management. Given challenges associated with coverage, potential self-sampling techniques, particularly resource-limited settings, discussed as means enhance accessibility participation cancer programs. By providing comprehensive overview these interrelated factors, this highlights necessity multidisciplinary approach integrates novel strategies, targeted efforts, supportive care mitigate burden HPV-associated diseases.

Language: Английский

Citations

0
Progress in the Study of Cervical Cancer Screening Methods DOI

祺 孙

Advances in Clinical Medicine, Journal Year: 2025, Volume and Issue: 15(03), P. 1989 - 1998

Published: Jan. 1, 2025

Language: Английский

Citations

0
Oncogenic roles and related mechanisms of the long non-coding RNA MINCR in human cancers DOI Creative Commons
Ce Chao,

Renzhe Tang,

Jiamin Zhao

et al.

Frontiers in Cell and Developmental Biology, Journal Year: 2023, Volume and Issue: 11

Published: May 5, 2023

Long non-coding RNAs (lncRNAs) play vital roles in regulating epigenetic mechanisms and gene expression levels, their dysregulation is closely associated with a variety of diseases such as cancer. Several studies have demonstrated that lncRNAs are dysregulated during tumor progression. Recently, the MYC-induced long RNA MINCR, newly identified lncRNA, has been to act an oncogene different cancers, including gallbladder cancer, hepatocellular colorectal non-small cell lung oral squamous carcinoma, nasopharyngeal glioma. Moreover, MINCR reported biomarker prognosis patients cancers. In this review, we summarize analyze oncogenic human cancers terms its clinical significance, biological functions, cellular activities, regulatory mechanism. Our analysis literature suggests potential novel therapeutic target

Language: Английский

Citations

10
Usefulness of high‐risk HPV early oncoprotein (E6 and E7) serological markers in the detection of cervical cancer: A systematic review and meta‐analysis DOI Creative Commons
Mwiza Gideon Singini, Elvira Singh, Debbie Bradshaw

et al.

Journal of Medical Virology, Journal Year: 2022, Volume and Issue: 95(1)

Published: June 1, 2022

We reviewed the literature on importance of selected anti-high-risk human papillomavirus (HR-HPV) antibodies (namely, 16/18 and early oncoproteins E6 E7) as potential serological markers for detection individuals at high risk cervical cancer. searched studies in PubMed Embase databases published from 2010 to 2020 against HR-HPV E7 proteins Pooled sensitivity specificity HPV16 HPV18 were calculated using a bivariate hierarchical random-effects model. A total 69 articles identified; we included three with 1550 participants. For HPV16/18 antibody tests, enzyme-linked immunosorbent assay-based assays had 18% detecting CIN2+ (95% confidence interval [CI]: 15-21) 96% CI: 92-98), slot-blot, was 28.9% 23.3-35.1) 72% 66.6-77.0) CIN2+, multiplex HPV serology assay based glutathione S-transferase, 16% 8.45-28.6) 98% 97-99) invasive HR-HPV16/18 showed specificity, but suboptimal cancer either population screening settings or point-of-care tests.

Language: Английский

Citations

14
Genetic variability of human papillomavirus type 18 based on E6, E7 and L1 genes in central China DOI Creative Commons
Ting Li,

Zhiping Yang,

Ping Luo

et al.

Virology Journal, Journal Year: 2024, Volume and Issue: 21(1)

Published: July 5, 2024

High-risk human papillomavirus (HR-HPV) infection is an important factor for the development of cervical cancer. HPV18 second most common HR-HPV after HPV16.

Language: Английский

Citations

1
The potential role of HPV oncoproteins in the PD-L1/PD-1 pathway in cervical cancer: new perspectives on cervical cancer immunotherapy DOI Creative Commons
Jin Li, Yuhong Ma, Qing-Feng Wu

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Dec. 13, 2024

Cervical cancer (CC) is a common malignant tumour of the female reproductive system that highly harmful to women’s health. The efficacy traditional surgery, radiotherapy and chemotherapy limited, especially for recurrent metastatic CC. With continuous progress in diagnostic treatment technology, immunotherapy has become new approach treating CC therapy However, not effective all patients with Therefore, factors related have focus researchers. High-risk human papillomavirus (HPV) infection an important factor drives development affects its progression prognosis. Increasing attention been given mechanism E5, E6 E7 proteins, which are encoded by HPV gene, occurrence their interaction programmed cell death ligand-1/programmed death-1 (PD-L1/PD-1). Although some preliminary studies conducted on these topics, comprehensive systematic review topics available. This comprehensively summarizes articles from journals impact greater than 3 published past 5 years; it also reviews CC, PD-L1/PD-1 axis regulation between HPV-related oncoproteins pathway prognosis study provides theoretical support use immunotherapies basis selection specific medications target different perspective discovery targets

Language: Английский

Citations

1